Real-world data showed Gilenya reduced the annualized relapse rate and risk of relapse by around 50% versus interferons or glatiramer acetate Reducing the frequency and probability of future relapses in patients with MS is a key treatment goal, as relapses can significantly advance an individual’s level of disability Recovering from a relapse can take weeks […]
LAVAL, Quebec, Oct. 3, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) and Bausch + Lomb announced today that the U.S. Food and Drug Administration (FDA) has issued marketing clearance for Bausch + Lomb’s newest frequent replacement silicone hydrogel contact lenses made with MoistureSeal™ Technology. Representing the category’s first new innovation […]
LAVAL, Quebec, Oct. 3, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that its wholly owned subsidiary, Valeant Canada LP, has received notice that the New Drug Submission for Jublia® has been approved from the Canadian regulatory authority, Health Canada. Jublia® (efinaconazole 10% topical solution) is indicated for the […]
Stockholm, October 2 – Esteya®, an electronic brachytherapy system, has received 510(k) clearance from the US Food and Drug Administration (FDA), enabling medical centers in the United States to offer their patients with skin cancer a new treatment option. Esteya is a new approach for high precision skin cancer treatment. The system relies on a small […]
Holzkirchen, Germany, October 02, 2013 – The European Generic medicines Association (EGA) has named Sandoz’s Nick Haggar as the new incoming president of the European generic medicines industry body. Nick will take over the role on October 8, 2013 alongside his responsibilities at Sandoz as Head of Western Europe, Middle East and Africa. “I am delighted […]
LAVAL, Quebec, Oct. 2, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced a partnership with the National Coalition Against Domestic Violence (NCADV) to help raise awareness of domestic violence. As part of the new domestic violence initiative, Valeant has pledged to donate a portion of sales from all Medicis and […]
Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder. Osaka, Japan and Copenhagen, Denmark—October 1, 2013—Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has approved Brintellix (vortioxetine) for the treatment of adults with major […]
Data Support Strong Statistical Association of PBC Biochemical Endpoint with Clinical Outcomes NEW YORK, Oct. 1, 2013 /PRNewswire/ — Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)(Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases such as primary biliary cirrhosis, today announced that two analyses by the Global Primary Biliary Cirrhosis (PBC) […]
WASHINGTON, Sept. 24, 2013 /PRNewswire/ — As Medicare and Medicaid brace for a continued influx of beneficiaries – many of whom are older and more likely to have chronic conditions including cancer – all players across the continuum of care need to work together, now, to implement innovative new care delivery models that can improve […]
Pilot Program Cuts Time for Clinicians to Obtain Supplies Nearly in Half DUBLIN, Ohio, Sept. 24, 2013 — Cardinal Health today unveiled its 2-Bin Kanban solution, an innovative approach to inventory management, at the Fall IDN Summit and Reverse Expo in Phoenix. The Cardinal Health 2-Bin Kanban solution combines principles of the Lean Six Sigma […]